Kyongbo Pharma says court stays product approval cancellations pending appeal ruling
Bitget2026/09/30 05:58- Kyongbo Pharmaceutical disclosed a court-ordered stay on the effectiveness of product license cancellations tied to its business suspension case.
- The stay runs until 30 days after an appellate ruling in the main lawsuit seeking to overturn the license-cancellation measure.
- The suspension-related affected sales were KRW 13.48 billion, equal to 5.65% of 2024 revenue of KRW 238.56 billion.
- The license cancellations had been set to take effect from June 24, 2025.
- The company plans to update disclosures depending on the appellate court’s decision on the merits.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley is tactically bullish on BHP (BHP.US): Two major copper mine catalysts may ignite the stock price in the next two months
Morgan Stanley maintains an "Overweight" rating on BHP Group, with an "attractive" industry outlook, and sets a target price of AUD 69.00 for its shares listed in Australia.
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
24 Hour Crypto Recap: Here’s What Happened in the Market
Crypto prices
More
